Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,055 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.
Hartikka J, Bozoukova V, Morrow J, Rusalov D, Shlapobersky M, Wei Q, Boutsaboualoy S, Ye M, Wloch MK, Doukas J, Sullivan S, Rolland A, Smith LR. Hartikka J, et al. Among authors: ye m. Hum Vaccin Immunother. 2012 Nov 1;8(11):1595-606. doi: 10.4161/hv.21225. Epub 2012 Aug 24. Hum Vaccin Immunother. 2012. PMID: 22922766 Free PMC article.
Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, Chaplin JA, Rusalov D, Rolland AP, Fisher CL, Al-Ibrahim MS, Kabongo ML, Steigbigel R, Belshe RB, Kitt ER, Chu AH, Moss RB. Smith LR, et al. Among authors: ye m. Vaccine. 2010 Mar 16;28(13):2565-72. doi: 10.1016/j.vaccine.2010.01.029. Epub 2010 Jan 29. Vaccine. 2010. PMID: 20117262 Clinical Trial.
Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and -Seropositive Healthy Subjects.
Bonate PL, Van Sant C, Cho K, Zook EC, Smith LR, Boutsaboualoy S, Ye M, Wang X, Wu R, Koester A, Rammelsberg D, Goldwater R, Marbury TC. Bonate PL, et al. Among authors: ye m. Clin Pharmacol Drug Dev. 2020 May;9(4):444-455. doi: 10.1002/cpdd.792. Epub 2020 Mar 23. Clin Pharmacol Drug Dev. 2020. PMID: 32202705 Clinical Trial.
Multiple epitopes in the murine cytomegalovirus early gene product M84 are efficiently presented in infected primary macrophages and contribute to strong CD8+-T-lymphocyte responses and protection following DNA immunization.
Ye M, Morello CS, Spector DH. Ye M, et al. J Virol. 2004 Oct;78(20):11233-45. doi: 10.1128/JVI.78.20.11233-11245.2004. J Virol. 2004. PMID: 15452242 Free PMC article.
However, the percentage of antigen-specific CD8(+) T cells elicited by IE1 was higher than that by M84 as measured by intracellular cytokine staining when splenocytes were stimulated with an epitope peptide (M. Ye at al., J. Virol. 76:2100-2112, 2002). We show here …
However, the percentage of antigen-specific CD8(+) T cells elicited by IE1 was higher than that by M84 as measured by intracellular cytokine …
5,055 results